Figure 2. INT2–31 reduces the viability and proliferation of melanoma cells. (A) Expression of constitutive FAK, IGF-1R, AKT and ERK in the three melanoma cell lines and melanocytes. (B) INT2–31 inhibited the cell viability (MTT assay) of normal melanocytes and three melanoma cell lines in a dose-dependent fashion over 72 h. (C) CSFE cell proliferation assay with C8161 melanoma cells (left) and A375 melanoma cells (right) in the presence of increasing doses of INT2–31 or TAE 226 (dual FAK and IGF-1R kinase inhibitor) was performed at 24, 48 and 72 h. Representative data are shown after 48 h of treatment. (D) C8161 melanoma cell counts at 24, 48 and 72 h in the presence of INT2–31 or TAE 226. Shown figures are representative of experiments performed in triplicate.